1959 - Member of the National Academy of Sciences
1905 - Fellow of the Royal Society of Canada
William C. Wood mostly deals with Surgery, Breast cancer, Internal medicine, Oncology and Cancer. William C. Wood has included themes like Primary tumor and Metastasis in his Surgery study. His research integrates issues of Chemotherapy regimen, Chemotherapy, Adjuvant therapy and Disease in his study of Breast cancer.
His work focuses on many connections between Internal medicine and other disciplines, such as Gastroenterology, that overlap with his field of interest in Liver transplantation, Relative risk and Fulminant. His biological study spans a wide range of topics, including Neoadjuvant therapy, Prospective cohort study, Oncotype DX, Biomarker and Mastectomy. The various areas that he examines in his Cancer study include Cancer research and Immunology.
His primary areas of study are Breast cancer, Internal medicine, Surgery, Oncology and Cancer. William C. Wood combines subjects such as Clinical trial, Gynecology and Adjuvant therapy with his study of Breast cancer. Internal medicine is closely attributed to Gastroenterology in his work.
His studies deal with areas such as Colorectal cancer and Carcinoma as well as Surgery. His study looks at the relationship between Oncology and fields such as Docetaxel, as well as how they intersect with chemical problems. His Cancer study deals with Pathology intersecting with Astrocytoma and Cytotoxicity.
The scientist’s investigation covers issues in Breast cancer, Internal medicine, Oncology, Surgery and Proportional hazards model. His studies in Breast cancer integrate themes in fields like Clinical endpoint, Radiation therapy, Adjuvant therapy and Hazard ratio. He interconnects Clinical trial, Chemotherapy, Docetaxel, Randomized controlled trial and Tamoxifen in the investigation of issues within Oncology.
His Chemotherapy study integrates concerns from other disciplines, such as Endocrine therapy and Capecitabine. His work carried out in the field of Surgery brings together such families of science as Gastroenterology, Liver function and New diagnosis. In Proportional hazards model, William C. Wood works on issues like Cohort, which are connected to Cohort study, Radiology, Meta-analysis, DCIS Score and Local excision.
William C. Wood mainly focuses on Internal medicine, Breast cancer, Oncology, Proportional hazards model and Randomized controlled trial. Internal medicine connects with themes related to Hepatectomy in his study. The Breast cancer study combines topics in areas such as Clinical trial, Chemotherapy, Adjuvant therapy, Biomarker and Radiation therapy.
His Oncology research includes themes of Prospective cohort study, Tamoxifen, Gynecology, Clinical endpoint and Mastectomy. His Proportional hazards model research is within the category of Surgery. His research in Surgery intersects with topics in Gastroenterology and Liver disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
I. Craig Henderson;Donald A. Berry;George D. Demetri;Constance T. Cirrincione.
Journal of Clinical Oncology (2003)
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
Hyman B. Muss;Ann D. Thor;Donald A. Berry;Timothy Kute.
The New England Journal of Medicine (1994)
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
A. Goldhirsch;W. C. Wood;R. D. Gelber;A. S. Coates.
Annals of Oncology (2007)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard.
The New England Journal of Medicine (2015)
Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer
Kevin S. Hughes;Lauren A. Schnaper;Donald Berry;Constance Cirrincione.
The New England Journal of Medicine (2004)
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
W C Wood;D R Budman;A H Korzun;M R Cooper.
The New England Journal of Medicine (1994)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard.
The New England Journal of Medicine (2018)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams;Robert J. Gray;Sandra Demaria;Lori Goldstein.
Journal of Clinical Oncology (2014)
Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343
Kevin S. Hughes;Lauren A. Schnaper;Jennifer R. Bellon;Constance T. Cirrincione.
Journal of Clinical Oncology (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: